Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Aventis sniffing out trouble

Executive Summary

Aventis is building a promotional campaign for Allegra around Schering-Plough's corporate-wide good manufacturing compliance difficulties. Aventis issued a press release March 14 declaring that it is "increasing production" of Allegra "to assure both patients and physicians that there will be an ample supply" for the spring allergy season. Aventis added that it is "taking steps to make increased supplies" of Nasacort AQ available, and that it is "prepared with substantial supplies of Azmacort." Schering-Plough says its supplies of Claritin are sufficient for the spring allergy season (1"The Pink Sheet" March 5, p. 6)

You may also be interested in...

Claritin Supply Sufficient For Spring, Schering Says; FDA Lists GMP Problems

Schering-Plough will have a sufficient supply of Claritin for the spring allergy season, the company maintains.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts